Blockade with an antibody that was raised against the binding site of Mac-1 for GPIbα without affecting other Mac-1 adhesive interactions resulted in a prolonged reduction of clinical encephalomyelitis symptoms as compared with the control antibody administration. The gene discussed is ITGAM; the disease is encephalomyelitis.